|
Real-time Estimate
Cboe BZX
01:22:17 03/10/2026 am IST
|
5-day change | 1st Jan Change | ||
| 4.555 USD | +2.59% |
|
-2.03% | -29.02% |
| 17/09 | Aquestive Therapeutics Resubmits New Drug Application to FDA for Anaphylm (Dibutepinephrine) Sublingual Film | CI |
| 17/09 | Aquestive Therapeutics Resubmits Anaphylm NDA to FDA | MT |
Turnover - Evolution of Analysts' Estimates
Earnings Per Share (EPS) - Evolution of Analysts' Estimates
EBIT - Evolution of Analysts' Estimates
Cash or Net Debt - Evolution of Analysts' Estimates
| 1m. Revenue rev. | 1y. Revenue rev. | 1y. EPS revision | ||
|---|---|---|---|---|
 | ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| Average | ||||
| Weighted average by Cap. |
Turnover
Earnings Per Share (EPS)
EBIT
Cash or Net Debt
- Stock Market
- Stocks
- AQST Stock
- Consensus Aquestive Therapeutics, Inc.
- Estimates Revisions
Select your edition
All financial news and data tailored to specific country editions
